Biomarker-Selected Treatment Shows Promise for Bladder Preservation in MIBC

(MedPage Today) -- Biomarker-driven treatment for muscle-invasive bladder cancer (MIBC) led to a 2-year metastasis-free survival (MFS) rate that exceeded 70% in a phase II study, but failed to meet prespecified statistical constraints for a positive...